CODX (Co-Diagnostics) Quality Rank

View and export this data going back to 2017. Start your Free Trial

What is Co-Diagnostics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Co-Diagnostics Quality Rank Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Co-Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

0A50:UK C97:Germany

Address

2401 South Foothill Drive, Salt Lake City, UT, USA, 84109

Website

https://www.codiagnostics.com

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Executives

Brian Lee Brown	officer: Chief Financial Officer	5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy	director	64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard	director	2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan	director, officer: CEO and President	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson	director	26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson	officer: CFO and Secretary	7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy	director	2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield	director, officer: Chief Science Officer	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc	10 percent owner	1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski	director	1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner	director	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc	10 percent owner	8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc	10 percent owner	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124